Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

MicroBLITZ in R/R NHBCell l Lymphomas (BMS CA209-8M7) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out microtransplantation (MST) combined with the study drug nivolumab is safe and effective for patients with relapsed or refractory B cell lymphomas.
What is the Condition Being Studied?
Relapsed or Refractory B Cell Lymphomas

Who Can Participate in the Study?

Adults who have relapsed/refractory B cell lymphomas

Age Group
Adults

What is Involved?

If you choose to be in the study you will be asked to go through a medical screening that includes a physical, a heart test (EKG and Echo) and a breathing test.

If still eligible you will be asked to:
-Take the study medication as directed
-Complete about 6 CT or PET Scans (Body scans) over 2 years
-Blood draws

Study Details

Full Title
MicroBLITZ: Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00101349
NCT: NCT03920631
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698